Abarceo Pharma has identified a novel diabetes target located on beta cells and a novel mechanism of action enabling a therapeutic treatment to revert beta cells from dysfunctional to functional, preserving beta cell function and allowing patients to produce their insulin again, naturally.

Abarceo is in the preclinical phase of drug development.

Reviving Beta Cells

 

About us

Tara Heitner

CEO & Founder

Kristian Hansen

CSO

 

Contact

© 2018 by Abarceo Pharma AB

Abarceo Pharma AB

Medeon Science Park, Inkubatorn, Per Albin Hanssons väg 41, 205 12 Malmö, Sweden, 

reg. no 559139-7160